Lack of sleep may increase IFG risk, study finds
NEW YORK Lack of beauty sleep may up one’s risk of developing a condition that leads to diabetes and heart disease, a new study found.
Researchers from Warwick Medical School and the State University of New York at Buffalo examined six years of data from 1,455 participants in the Western New York Health Study, all of whom were between the ages of 35 and 79 years, and found that people who sleep less than six hours a night may be three times more likely to develop incident-impaired fasting glycaemia. IFG causes the body to be unable to regulate glucose as efficiently as it should.
Lead author at Warwick Medical School Dr. Saverio Stranges said: "We found that short sleep, less than six hours, was associated with a significant, threefold increased likelihood of developing IFG, compared [with] people who got an average of six to eight hours sleep a night. Previous studies have shown that short sleep duration results in a 28% increase in mean levels of the appetite stimulating hormone ghrelin so it can affect feeding behaviors. Other studies have also shown that a lack of sleep can decrease glucose tolerance and increases the production of cortisol, a hormone produced in response to stress."
Stranges added that, "more research is needed, but our study does suggest a very strong correlation between lack of sleep and Type 2 diabetes and heart disease."
The study was published in the journal Annals of Epidemiology.
Bayer Consumer Care adds two products to One A Day line
MORRISTOWN, N.J. Bayer Consumer Care on Tuesday introduced two new gender-specific multivitamins: One A Day Menopause Formula and One A Day Men’s Pro Edge.
One A Day Menopause Formula is a complete multivitamin formulated with soy isoflavones to help address hot flashes and mild mood changes.
"It can often be a challenge for women going through this new life stage to get the nutrients they need," stated diet and nutrition expert Madelyn Fernstrom. "Even with a healthy diet, supplementation may be needed to get adequate amounts of the nutrients important to this age group, particularly vitamin D and calcium. This can help support a healthy lifestyle for women as they enter this stage of their lives."
In addition, women going through menopause now have a new resource for information. LiveMenopause.com is dedicated to providing information about menopause and connecting women to others who are going through this stage of life.
Meanwhile, One A Day Men’s Pro Edge is a complete multivitamin that contains high levels of magnesium and vitamins A, B, C and E.
"Because men who are physically active exert more energy, they have an increased need for some nutrients to help their bodies refuel," Fernstrom said. "Though diet is the first source for nutritional needs, supplementation with a multivitamin can help provide extra nutrients to support optimal health for the busy, active man."
Decision Resources: Market for Alzheimer’s disease drugs will expand
BURLINGTON, Mass. Biotech drugs for treating Alzheimer’s disease will more than triple the size of the market in several key countries over the next decade, according to a new report by industry research company Decision Resources.
The report showed that bapineuzumab, made by Johnson & Johnson and Pfizer, and Eli Lilly’s solanezumab will drive the market for Alzheimer’s drugs from 2009’s $4.3 billion to $13.3 billion in 2019 in the United States, Japan, the United Kingdom, Germany, France, Italy and Spain.
Whereas most current Alzheimer’s drugs are acetylcholinesterase inhibitors, or AChEIs, which treat the disease’s cognitive symptoms without modifying its course, the new drugs have the potential to slow the rate of neural degeneration and cognitive decline, according to the report. Still, sales of AChEIs will remain strong through the decade.
“Despite increased generic competition and the launch of more-expensive and potentially more-efficacious therapies, AChEI sales will be buoyed through 2019,” Decision Resources director Bethany Kiernan said. “This will be largely due to an overall market expansion driven by increases in the number of drug-treated patients but also, to a lesser extent, by the launch of new formulations of branded AChEIs.”